1. Home
  2. TENX vs CAES Comparison

TENX vs CAES Comparison

Compare TENX & CAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$14.82

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

CAES

Cantor Equity Partners VII Inc. Class A Ordinary Shares

N/A

Current Price

$10.06

Market Cap

320.7M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TENX
CAES
Founded
1967
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
317.8M
320.7M
IPO Year
2001
2026

Fundamental Metrics

Financial Performance
Metric
TENX
CAES
Price
$14.82
$10.06
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$29.67
N/A
AVG Volume (30 Days)
1.3M
75.2K
Earning Date
05-15-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.80
$10.05
52 Week High
$19.40
$10.12

Technical Indicators

Market Signals
Indicator
TENX
CAES
Relative Strength Index (RSI) 49.73 44.65
Support Level $13.13 N/A
Resistance Level $16.35 $10.09
Average True Range (ATR) 1.20 0.02
MACD -0.22 -0.00
Stochastic Oscillator 19.95 33.33

Price Performance

Historical Comparison
TENX
CAES

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About CAES Cantor Equity Partners VII Inc. Class A Ordinary Shares

Cantor Equity Partners VII Inc is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: